Coverage / CLRB / Trade Card

CLRB

Cellectar Biosciences Inc

OPPORTUNISTIC BUY 2026-08-01 Updated today USD 2.57 Healthcare - BiotechnologyIN BUY ZONE
62

Position levels

Currenttoday
USD 2.57
Buy <=wait / entry
USD 2.67
Trim >=take some off
USD 5.00
Thesis breakA pivotal study failure for iopofosine I 131, a Complete Response Letter or refu...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case30%100 / 10030.0
Base case49%62 / 10030.4
Bear case21%10 / 1002.1
Weighted conviction62 / 100 - OPPORTUNISTIC BUY

Top risks

  • Q1 2026 EPS beat of 25.28% versus analyst estimates
  • Strong Buy consensus from 2 analysts with $11.00 price target
  • Increased projected peak revenues for iopofosine 131I to $340 million by 2030
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.